article
COVID-19: a wakeup call?
It appears the world was unprepared for a novel coronavirus, despite historical precedents. Dave Elder provides some insight on the disease and what the pharmaceutical community is doing to tackle the pandemic.
List view / Grid view
Ebola
Filter the results
article
Summarising 2019: a year of firsts for the EMA
The EMA was a proactive force in 2019, granting marketing authorisation for a range of drugs. This article highlights some of the most important advancements made by the agency last year.
news
J&J to provide 200,000 Ebola vaccine regimens to Rwanda
Johnson & Johnson has announced that it will be contributing vaccines to support the Rwandan immunisation programme to combat Ebola.
news
EU Marketing Authorisation submitted for Ebola vaccine regimen
Janssen has submitted two Marketing Authorisation Applications to the EMA for an investigational Ebola vaccine regimen.
news
Ebola vaccines donated to Democratic Republic of Congo
500,000 regimens of Janssen's investigational Ebola vaccine are to be donated to support the Ebola outbreak response in the Democratic Republic of the Congo.
news
Seven medicines recommended for approval by EMA
The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.
news
DRC to use a second Ebola vaccine by November
The Democratic Republic of Congo will introduce a second Ebola vaccine next month to counter the outbreak of the disease in the country.
news
DRC announces plans to use second Ebola vaccine
Health authorities in the Democratic Republic of Congo are planning to use a second vaccine to treat the Ebola virus.
news
FDA accepts Biologics License Application for V920 Ebola vaccine
A Biologics License Application and priority review has been approved by the FDA for an investigational Ebola vaccine.
news
$23m aid announced for Ebola vaccine manufacture
The US HHS has committed to a contribution to help Merck manufacture its investigational V920 vaccine for the treatment of Ebola.
news
Ebola clinical trial stopped early due to positive results
An Ebola clinical trial has been stopped early as Regeneron's REGN-EB3 therapy shows superiority to ZMapp in preventing Ebola deaths.
article
Climate change: how pharma will profit from a warming planet
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
news
DRC rejects clinical trial for experimental Ebola vaccine
The health minister for the Democratic Republic of the Congo has stated an experimental Ebola vaccine will not be trialled in the country.
news
Report suggests process for vaccine trials during health crises
A recent report has presented an argument for updating vaccine development during health emergencies to increase efficiency.
news
Vaccine facility targets development and manufacturing to fight pandemics
The new hub is designed to speed the response to deadly pandemics by improving the development and manufacturing of vaccines – particularly in low- and middle-income countries...